Abstract Basal breast cancer, common among patients presenting with inflammatory breast cancer (IBC), has been shown to be resistant to radiation and enriched in cancer stem cells. The Notch pathway plays an important role in self-renewal of breast cancer stem cells and contributes to inflammatory signaling which promotes the breast cancer stem cell phenotype. Herein, we inhibited Notch signaling using a gamma secretase inhibitor, RO4929097, in an in vitro model that enriches for cancer initiating cells (3D clonogenic assay) and conventional 2D clonogenic assay to compare the effect on radiosensitization of the SUM149 and SUM190 IBC cell lines. RO4929097 downregulated the Notch target genes Hes1, Hey1, and HeyL, and showed a significant reduction in anchorage independent growth in SUM190 and SUM149. However, the putative self-renewal assay mammosphere formation efficiency was increased with the drug. To assess radiosensitization of putative cancer stem cells, cells were exposed to increasing doses of radiation with or without 1 lM RO4929097 in their standard (2D) and self-renewal enriching (3D) culture conditions. In the conventional 2D clonogenic assay, RO4929097 significantly sensitized SUM190 cells to ionizing radiation and has a modest radiosensitization effect in SUM149 cells. In the 3D clonogenic assays, however, a radioprotective effect was seen in both SUM149 and SUM190 cells at higher doses.
Introduction
In breast cancer and other solid tumors, there is increasing evidence suggesting that aggressive basal tumor types are enriched for a subpopulation of cells called cancer stem cells (CSCs) or tumor-initiating cells. These cells drive tumor formation when transplanted into immunocompromised mice, undergo self-renewal, and re-populate the tumor bulk and its heterogeneity. They are believed to contribute to therapeutic resistance and tumor metastasis or local recurrence [1] [2] [3] [4] [5] [6] [7] [8] [9] . Human breast CSCs can be enriched by cell surface markers CD44
? CD24 low and by aldehyde dehydrogenase (ALDH) enzyme activity as ALDH? cells [10, 11] . In vitro propagation as mammospheres also enriches the CSC population [12] .
Inflammatory breast cancer (IBC) is the most aggressive form of breast cancer accounting for 2.5 % of all breast cancer cases. It is characterized by rapid progression, local and distant metastases, younger age of onset, and lower overall survival compared with other breast cancers [13] . The prognosis of patients with IBC has only improved slightly with standard therapies over the last 10-15 years. Recent studies have indicated that the metastatic, aggressive behavior of IBC may be mediated by the stem cell phenotype. By the Mary-X model of IBC, Barsky's group showed that tumor spheroids expressed a CSC profile characterized by CD44
? CD24 low , ALDH1, and CD133 consistent with Mary-X spheroids having characteristics of CSCs [14] . Most recently, the Mary-X IBC model was shown to have a significant ALDH? subpopulation which exhibited a stem cell-like phenotype including secondary spheroid formation, high tumorigenicity, and self-renewal [15] . In other studies, the IBC cell line SUM149 was documented to express the putative stem cell surface markers CD44
? CD24 low and ALDH1 [5, 16] . Consistent with previous studies, Charafe-Jauffret et al. [17] showed recently that cells from SUM149 and Mary X possess a subpopulation of ALDH1? cells that mediate invasiveness and metastasis and that the expression of ALDH1 protein in tissue sections from patients with IBC was an independent prognostic marker to predict metastasis and poor patient outcome. Altogether, the studies suggest that the angioinvasive and metastatic nature of IBC may be attributed to its stem cell phenotype. Thus, targeting the CSC subpopulation in IBC is of great interest. One approach is to target signaling pathways that are critical for the self-renewal and survival of CSCs, and several candidate pathways have been identified including Notch, Wnt, and Hedgehog (reviewed in [18] ).
Notch proteins are a family of transmembrane receptors that play an essential role in cell fate decisions such as proliferation, differentiation, and apoptosis. Notch receptors are encoded by four mammalian genes. Notch receptors are synthesized as a single peptide, but an S1 cleavage in the Golgi separates the extracellular and transmembrane domains before localization to the plasma membrane. Binding one of the cognate ligands initiates an S2 cleavage by the metalloprotease TACE (tumor necrosis factor alphaconverting enzyme) freeing the extracellular domain and providing a substrate for the c-secretase complex consisting of presenilins, APH1, and PEN2. The c-secretase activity creates a S3 cleavage that frees the Notch Intracellular Domain (NICD) from the membrane conferring transcriptional competence [19] . After translocating to the nucleus, NICD binds the transcription complex RBP-Jj (also known as CSL) via the RBP-Jj-associated module (RAM) domain displacing repressor proteins and initiating transcription that induces target gene expression including members of the Hes and Hey families of transcription factors [19] Therefore, preventing the S3 cleavage with a gamma-secretase inhibitor (GSI) will retain NICD at the membrane and prevent signaling.
Notch signaling has been shown to play an important role in stem cell self-renewal and differentiation. Dontu et al. [20] showed that Notch signaling was important to maintaining the stem cell phenotype of mammosphere cultures. Specifically, this study demonstrated addition of a Notch-activating peptide caused a tenfold increase in secondary and tertiary mammosphere formation while inhibiting Notch signaling with blocking antibody or GSI abolished secondary mammosphere formation. Another study demonstrated that CSCs from breast cancer cell lines and patient samples expressed higher levels of Notch4, but not Notch1; inhibition of Notch4 was more effective in reducing tumor initiation than Notch1 [21] . More recently, Grudzien et al. [22] showed the role of Notch signaling in the maintenance of breast cancer stem-like cells through genomic and pharmacologic inhibition of Notch that reduced the stem-like population of breast cancer cells and prevented mammosphere formation. In a study relating the stem cell phenotype in the IBC model of Mary-X and Notch signaling, Xiao et al. [15] observed that the sorted ALDH1? subpopulation exhibited enriched Notch3 downstream signaling and co-localization of Notch3 and ALDH1 were demonstrated within the lymphovascular emboli of Mary-X. Inhibiting Notch3 activation in vitro with GSIs or small interfering RNA resulted in a downregulation of Notch target genes and induction of apoptosis [15] . The Notch pathway has also been linked to radiation resistance in breast cancer stem cells. Phillips et al. [2] demonstrated the radioresistance of putative breast cancer stem/progenitor cells by comparing the radiosensitivity of cells derived from the CD44
? CD24 -subpopulation of MCF-7 cell line grown as spheres versus monolayers and showed the Notch signaling pathway as the mediator of radioresistance. Thus, the Notch pathway is a potential target to improve radiosensitization of CSCs.
Numerous studies have suggested that cell-extrinsic factors from the tumor microenvironment may be critical in controlling tumor progression [23] [24] [25] [26] . In particular, polarized immune responses have been shown to promote metastasis [27] . Furthermore, activated immune cells produce inflammatory factors that have been associated with stem cell induction in SUM159 and SUM149 [28] . NF-jB activation by TNF-a in particular has been shown to induce a stem-like state [29] . Notch has been shown to play a role in T-cell polarization of TH2 cells [30] [31] [32] that may promote tumor growth, and in contrast, changes the balance in favor of TH1 cells [33] that are involved in the cytolytic response. TH2 cells are capable of producing small amounts of IL-6, a factor associated with stem cell regulation [28] . More importantly, TH2 cells induce IL-6 synthesis by macrophages [34] . Thus, immune cells may play a role in the induction and maintenance of stem-like cells. It has also been suggested that delta-like ligands promote Notch3-mediated transcription of T-bet and therefore TH1 polarization, whereas jagged ligands promote Notch1 and 2 activation of Gata3 and the TH2 cytokine IL-4 [35] . As such, the exact role of Notch in T-cell activation remains controversial [36] , but the potential for regulating microenvironmental inflammatory cues is intriguing.
In this study, we sought to inhibit Notch signaling using a potent and selective inhibitor of gamma secretase, RO4929097 [37, 38] , in an in vitro model that enriches CSCs (3D clonogenic assay) and conventional 2D clonogenic assay, and assess its effect on radiosensitization of the IBC cell lines SUM149 and SUM190. Moreover, since inflammatory signaling has been associated with the promotion and maintenance of CSCs [29] , we also evaluated the effect of GSI on inflammatory cytokine production to evaluate a dual tumor inhibitory function for GSI targeting both the tumor cells and the host.
Materials and methods

Cell culture
For sphere formation, SUM149 and SUM190 cells were placed in ultralow attachment dishes (Corning, NY) in mammosphere media as previously described by Dontu et al. [12] . Briefly, single cells were seeded in 6-well ultralow attachment plates (Corning, NY) in serum-free MEM media supplemented with 20 ng/ml bFGF, 20 ng/ml EGF, and B27 (Invitrogen). Adherent cells were grown on standard tissue culture plate in growth media that contains Ham's F12 with 10 % fetal bovine serum (FBS), insulin, hydrocortisone, and penicillin-streptomycin.
Aldefluor assay and sorting of ALDH negative/positive population The Aldefluor assay was performed following the manufacturer's guidelines (StemCell Technologies, Vancouver, Canada). Briefly, about 5 9 10 5 cells were suspended in Aldefluor assay buffer containing ALDH substrate and incubated for 30 min at 37°C. As a negative control for each sample, a sample of cells was incubated with 50 mmol/l of the specific ALDH inhibitor diethylaminobenzaldehyde (DEAB). Aldefluor fluorescence was excited at 488 nm and fluorescence emission was detected using FACSAria II flow cytometer from Becton-Dickinson (BD Biosciences, San Jose, USA. The data files were analyzed using FlowJo software (Treestar, Ashland, OR). For sorting, gates were established using ALDH-stained cells treated with DEAB as negative controls and taking the high negative and positive cells (Fig. 1a) .
RNA isolation and RT-PCR
After sorting SUM149 cells into ALDH? or ALDH-subpopulation, total RNA was isolated using Trizol reagent (Invitrogen) according to the manufacturer's protocol. After treatment with DNase I (Ambion), two micrograms of the RNA samples were reverse transcribed with random hexamers using Super Script III First-Strand Synthesis System (Invitrogen To assess the effect of RO4929097 on the Notch signaling pathway, SUM149 and SUM190 cells were seeded on a 10-cm plate, left to attach overnight followed by treatment the next day. RNA was extracted using the RNeasy Mini Kit (Qiagen, City, CA) and gene expression analysis performed using SABiosciences RT2 Profiler Notch Signaling Pathway PCR Array (PAHS-059) as per the manufacturer's protocol. PCR was performed on 7300 Real-Time PCR equipment (Applied Biosystems, Foster City, CA). Data were analyzed using an Excel-based data analysis system (SABiosciences) that is based on the DDCt method. Normalization of the raw data was made to one or more of the housekeeping genes in the array.
Cell proliferation, anchorage independent growth, and invasion assay The IBC cell lines SUM149 and SUM190 were seeded at a density of 5 9 10 4 cells. The next day, they were treated with vehicle or increasing doses of RO4929097, ranging from 0.1 nM to 10 lM. After 72 h, cells were trypsinized and viable cells counted using a hemocytometer. Anchorage-independent growth was assessed by a soft agar colony assay. Briefly, this assay was performed in six-well plates with a base of 2 ml of medium containing 1 % FBS and 0.5 % agarose (Fisher, BP1360-100). About 5 9 10 4 SUM149 and SUM190 cells were layered onto the base in 2 ml of medium containing 1 % FBS and 0.35 % agar. The experiments were performed in triplicate and repeated twice. An invasion assay was carried out using a modified Boyden chamber to evaluate the capability of tumor cells to migrate through Matrigel. Briefly, 2.5 9 10 4 SUM149 cells were plated onto each BD BioCoat GFR Matrigel invasion chamber insert (24-well insert; pore size, 8 mm; BD Biosciences). The medium in the upper compartment was serum-free RPMI-1640 supplemented with 0.2 lM purified Glu-plasminogen (American Diagnostica, Greenwich, CT), and 5 % FBS was used as a chemoattractant in the lower compartment. After incubation for 24 h in a humidified tissue culture incubator at 37°C with 5 % CO 2 , the non-invading cells were removed from the upper surface of the membrane by scrubbing. The migrated cells were fixed with 4 % paraformaldehyde and stained with crystal-violet. For quantification, the average number of migrating cells was calculated by counting five random fields in the central region of the membrane using a light microscope. Data represent the mean number of migrating cells obtained from triplicate membranes.
Clonogenic/3D mammosphere formation assay
This was conducted as previously described [39] . Briefly, monolayer cultures of both IBC cell lines were trypsinized into single cells and were seeded into individual wells of a 6-well tissue culture plate (for 2D) or ultralow attachment plates (for 3D, 20,000 cells/ml) in the presence or absence of 1 lM RO4929097. Then the 2D and 3D six-well plates containing seeded single cells were exposed to increasing doses of irradiation (0, 2, 4, or 6 Gy) 4 h after plating. For Figs. 4a and b, however, SUM149 2D monolayer cells were also pre-treated with 1 lM RO4929097 or vehicle for 24 h to see if cell contact had an effect. 2D plates were incubated for 14 days and colonies were stained with b ALDH-or ALDH? (from a) were subjected to RT-PCR for Notch gene expression. Results indicate that ALDH ? SUM149 cells express Notch 1, 2, and 3 at slightly higher levels than ALDHcells. Notch4 was not detected crystal violet, while 3D cells were incubated in mammosphere media for 7 days; the spheres were assessed for proliferation using the MTT assay and those with a size of 50 lM were counted using a Gelcount colony counter (Oxford Optronix, Oxford, UK). For secondary mammosphere assay, cells from primary mammospheres were dispersed with 0.05 % trypsin, seeded in six-well ultra-low attachment plates (10,000 cells/ml) in mammosphere media and counted after a week. Survival curves were generated by Sigmaplot 8.0.
Immunoblotting
Cell extracts were prepared from 2D monolayer and 3D sphere cultures of SUM149 cells in the presence or absence of 1 lM RO4929097 and with or without exposure to 4 Gy of radiation based on clonogenic data. The cells were scraped and lysed with cell lysis buffer (Cell Signaling, City, MA), supplemented with protease inhibitor (1 mM phenylmethanesulfonyl fluoride, PMSF). Protein concentrations were determined by the Bio-Rad Protein Assay (Bio-Rad, Hercules, CA) and 40 lg of each samples were separated using 4-20 % Tris-HCl polyacrylamide gel (Invitrogen, City, CA) and transferred onto a PVDF membrane from Bio-Rad. The membranes were blocked in 5 % milk powder in TBS-T for *1 h and were then incubated with the primary antibodies to b-catenin and survivin (cell signal). Membranes were washed three times and incubated with the corresponding secondary antibody conjugated with horseradish peroxidase in 5 % nonfat milk at room temperature. After incubation with secondary antibody, the membranes were washed three times and immunoreactivity was detected by enhanced chemiluminescence. Anti-actin (Sigma) antibody was used as a loading control.
Cytokine measurement
The Luminex multiplex bead array was used to measure cytokines in culture supernatants of breast cancer cell lines, as we previously described [40] . Briefly, breast cancer cell lines SUM149, SUM190, and KPL4 were grown on plastic in 2D conditions. The non-IBC cell lines MCF-7, MDA-231, MDA-453, SKBR3, and BT474 were cultured in DMEM supplemented with 10 % FBS and penicillinstreptomycin. Cell culture supernatants were collected when the cultures reached 80 % confluence, centrifuged at 4009g to remove cellular debris, and then frozen at -80°C until analysis. Cytokine concentrations were measured using Milliplex MAP Human Cytokine/Chemokine Panel as per the manufacturer's protocol (EMD Millipore, Billerica, MA) and analyzed by a Luminex 100 Analyzer running BioPlex 4.2 Software (Bio-Rad).
Effect of GSI RO4929097 on T-cell cytokine synthesis Peripheral blood was collected by venipuncture from healthy volunteers. Peripheral blood mononuclear cells (PBMC) were isolated by density gradient centrifugation over Ficoll-Paque Plus (GE Healthcare, Piscataway, NJ), washed with phosphate buffered saline and resuspended at 1 9 10 6 per ml in RPMI ? 10 % FBS) with penicillinstreptomycin (RPMI and antibiotic cocktail from Cellgro by MediaTech Inc., Manassas, VA; certified FBS from Gibco by Life Technologies, Carlsbad, CA). 1.5 9 10 6 PBMC were stimulated in six-well plates with 200 lg/ml immobilized anti-CD3 antibody (Beckman Coulter, Brea, CA) plus soluble anti-CD28 antibody (final concentration 1.5 lg/ml, BD Biosciences, San Jose, CA) or left unstimulated in uncoated wells as previously published [41] . To test the effects of gamma-secretase inhibition, GSI RO4929097 or DMSO as a vehicle control was added as indicated and incubated at 37°C in 5 % CO 2 for 36 h. The Golgi transport inhibitor brefeldin A (Sigma-Aldrich, St. Louis, MO) was added at a final concentration of 10 lg/ml the final 4 h for intracellular cytokine production. Following stimulation, samples were fixed with FACS Lyse (BD Biosciences) and the cell membranes were permeablized with BD FACS Permeabilizing Solution 2. Aliqouts were stained with a cocktail of monoclonal antibodies against surface antigens (CD3, CD4, and CD69) and a panel of cytokines: IFN-c, IL-2, IL-4 ? IL-13 (TH2), IL-10, IL-17, or TNF-a. Unpermeablized cells were stained for the surface phenotypic markers CD3 and CD4 and the activation markers CCR7, CD25, and CD69. Four-color cytometric evaluation was acquired on a BD FACS Calibur flow cytometer and the data analyzed by FlowJo software (Treestar, Inc, Ashland, OR).
Statistical methods
Survival curves were generated by Sigmaplot 8.0 and t test was used to compare differences at each dose following normalization to the unirradiated samples. A p value of \0.05 in a paired two-sided t test was considered statistically significant.
Results
Expression of Notch receptors in IBC stem cell subpopulation
The stem cell marker ALDH has been previously reported in Mary-X tumor and SUM149 cell line [14, 15, 17] . By utilizing this stem cell marker, we sorted SUM149 cells
into ALDH-or ALDH? (Fig. 1a) and assessed the expression of the Notch receptors in the IBC stem cell population by RT-PCR. About twofold higher expression of Notch1, Notch2, and Notch3 receptors were found in the ALDH? subpopulation versus ALDH-subpopulation (Fig. 1b) . Notch4 was not detected in either of the population, while SUM190 IBC cells have very low (\1 %) ALDH? subpopulation (data not shown).
Gene expression changes of Notch downstream targets by RO429097
RO429097 is a gamma secretase small molecule inhibitor that prevents the proteolytic step that leads to the generation of the active intracellular domain of Notch, thus suppressing Notch signaling. In a previous study, RO4929097 inhibited Notch processing in human non-small cell lung carcinoma cells as measured by the reduction of intracellular Notch expression by western blot and reduced expression of the Notch transcriptional target gene Hes1 [37] . To confirm whether RO429097 targets Notch downstream genes in IBC cells, gene expression analysis was performed by Notch Signaling Pathway PCR Array in both SUM149 and SUM190 cell lines in 2D cultures treated with RO4929097 and compared with vehicle-treated controls. Treatment with the inhibitor showed a two-to threefold reduction in the expression of direct Notch target genes, Hes1, Hey1, and Heyl in SUM149 and a 3.5-to eightfold decrease in expression in SUM190 cells (Fig. 2a) .
RO429097 on growth characteristics of IBC cell lines
We assessed the efficacy of RO4929097 on cell proliferation and anchorage-independent growth in both IBC cell lines and invasion assay in SUM149 cells. For the proliferation assay, cells were treated with vehicle or increasing concentrations of the drug for 72 h before the number of viable cells was counted. Each of these cell lines showed modest growth inhibition with RO4929097 in a dose-dependent manner. At a concentration of 1 lM of RO4929097, growth inhibition was 20 % for SUM149 and 10 % for SUM190 cells, relative to vehicle-treated controls (Fig. 2b) . Anchorageindependent colony formation in soft agar has been used as a surrogate to assess tumorigenicity of cancer cells. As shown in Fig. 2c , a decrease in colony formation by SUM190 and SUM149 cells treated with RO4929097 was nearly 50 and 75 %, respectively at 10 lM (p \ 0.05).
The invasiveness of SUM149 cells in the presence of increasing doses of RO4929097 showed that the inhibitor does not have a marked effect in invasiveness of these cells (Fig. 2d ).
RO4929097 on 2D colony and 3D mammosphere formation in IBC cell lines
We next studied the ability of these IBC cell lines to form colonies when plated at clonal density on six-well cell culture plates in the presence or absence of 1 lM RO4929097 for 2 weeks. RO4929097 significantly reduced colony formation by both cell lines (p \ 0.05; Fig. 3a, c) with the effect being more notable in SUM149 than by SUM190 cells. CSCs are thought to possess the ability to self-renew similar to normal stem cells. The generation of mammospheres from single cells cultured under nonadherent conditions in growth factor-supplemented media is a widely used approach to enrich cancer stem/progenitor cells from cell lines and primary tumor samples. To evaluate whether RO4929097 has an effect on the formation of mammospheres in vitro, we exposed single cells from SUM149 and SUM190 cell lines to a vehicle or 1 lM RO4929097 for a week and counted the resultant spheres.
As shown in Fig. 3b and d, the inhibitor increased sphere formation significantly in both cell lines (p \ 0.05). We also examined secondary mammosphere formation to assess self-renewal ability upon passaging. A significant increase in secondary mammosphere formation was observed in SUM149 (p \ 0.05) with RO4929097 treatment, while no significant difference was observed in SUM190 cells.
RO4929097 treatment on radiation response of IBC cell lines
We then examined the effect of RO4929097 on sensitivity to radiation of SUM149 and SUM190 cells grown to form 2D colonies or 3D mammospheres. After treating with increasing doses of ionizing radiation in the presence or absence of the drug, 2D colonies were allowed to grow for 10-14 days, while the mammospheres were permitted to grow for 1 week. At 1 lM, RO4929097 was able to sensitize adherent cells to radiation with a more significant effect seen in SUM190 than in SUM149 cells (Fig. 4a, c) . However, the same dose of inhibitor radioprotected cells grown under conditions that favor the enrichment of the (Fig. 4b, d ). This discrepancy between 2D and 3D cultures suggested that cell contact may be needed for a Notch inhibitor to have a significant effect. To test this, we treated confluent SUM149 cells in monolayer with 1 lM RO4929097 or vehicle for 24 h. After 24 h, cells were seeded as single cells in a 2D or stem cell enriching 3D conditions containing 1 lM RO4929097 or vehicle. Four hours after seeding, cells were irradiated with single, increasing doses of radiation. We did not detect radiosensitization in either culture condition (Fig. 5a, b) . Similarly, using MCF7 spheres, adding the Notch inhibitor to the spheres and treating them with increasing doses of radiation was tested, but it did not increase radiosensitivity (data not shown). In an attempt to understand whether redundant stem cell survival pathways and downstream effectors may play a role in the radioprotection effect seen in 3D stem cell enriching cultures, protein lysates were prepared from 2D monolayer and 3D sphere cultures of SUM149 cells with and without 1 lM RO4929097 and 4 Gy ionizing radiation. We found that b-catenin and survivin were upregulated in 3D culture versus monolayer cells (Fig. 5c, d) . Moreover, treatment with 1 lM RO4929097 significantly upregulated survivin in 3D irradiated cells compared to untreated irradiated controls (Fig. 5c ).
High expression of IL-6 and IL-8 in IBC cell lines
As the inflammatory cytokines IL-6 and IL-8 were recently suggested to reduce the effectiveness of RO4929097 in vivo [38] , we tested the secretion of these factors by the IBC cell lines SUM149 and SUM190 vis-à-vis other non-IBC lines. SUM149 and SUM190 cells were the only tested breast cancer cell lines that secreted detectable levels of both of these cytokines (IL-8 ) IL-6, Fig. 6a, b) . We next tested the effect of RO4929097 on cytokine secretion by SUM149 and SUM190 cells in 2D and 3D. Both SUM149 and SUM190 secreted IL-6 and IL-8 in 2D culture, which persisted after treatment with RO4929097. Supernatants from cells grown in 3D had lower, but still detectable, concentrations of IL-6 and IL-8 compared to 2D cultures and were minimally decreased with RO4929097 treatment.
Effect of RO4929097 on cytokine synthesis and T-cell activation
As inflammatory cytokine signaling through IL-6 and IL-8 can be mediated in vivo by adaptive immune responses, we tested the effect of RO4929097 on cytokine production by TCR-activated T cells. To test the anti-inflammatory effects of RO4929097 on T cells, we measured intracellular cytokine production by normal PBMC following stimulation through the TCR in the presence of RO4929097. Fresh PBMC from healthy volunteers were stimulated with platebound anti-CD3 and soluble anti-CD28 antibodies for 36 h in the presence of 0.1 nM-10 lM RO4929097. Flow cytometry was used to quantify the percentage of T cells producing cytokines. T-cells are not a major source of IL-6 [42] or IL-8 [43] , but can influence the production of these cytokines by other cells. In particular, monocytes have a strong IL-6 response to TNF-a, and epithelial, endothelial, and fibroblast cells often secrete IL-6 in response to IL-17. Therefore, we focused on the canonical T-cell cytokines. IL-2, IFN-c, and TNF-a were measured to characterize a TH1-polarized response; IL-4, IL-13, and IL-10 for TH2 and IL-17 for TH17. In a serial dilution of GSI around the expected therapeutic range from 0.1 nM to 70 nm, there were no significant changes in the percentage of CD4 or CD8 T-cells producing IFN-c, IL-2, TNF-a, IL-4/IL-13, IL-10, or IL-17. However, there was a trend for a decreasing percentage of CD8 ? T cells producing IFN-c, IL-2, and TNF-a, CD4 cells producing IFN-c and IL-2, and a weak trend in decreasing production of the TH2 cytokines IL-4 and IL-13, but neither IL-10 nor IL-17 (data not shown).
To test the effect of high-dose RO4929097 on T-cell cytokine production, activated PBMC from two healthy donors were treated with 1 lM RO4929097, 10 lM RO4929097, or DMSO vehicle control. There was a reproducible trend in toward a decrease in the percentage of CD3 T cells which synthesized IFN-c, IL-2, and most notably TNF-a. After treating with DMSO vehicle, an average of 12.2 ± 2.91 % (mean ± SEM) of TCR-activated T cells produced TNF-a compared with 6.8 ± 1.23 % treated with 1 lM GSI and 4.5 ± 1.2 % treated with 10 lM RO4929097. Although the percentages of cells synthesizing TH2 cytokines were low, a decreasing trend was observed in the percentage of CD3 cells that synthesized the TH2 cytokines IL-4 ? IL-13 (Fig. 7) . The percentage of cells that synthesized IL-10 or IL-17 did not seem to be effected by RO4929097 treatment. These data suggest that treatment with RO4929097 can reduce the production of inflammatory cytokines by T-cells. Furthermore, with RO4929097 treatment, there was a shift in favor of TH2 over TH1 cytokines. As IL-6 is promoted by TH2 conditions, this would suggest that T-cell activation induced IL-6 production would be increased with RO4929097.
Next, to test if the reduction in inflammatory cytokine production was related to the activation of T-cells, we quantified the expression of the surface activation markers CD25 and CD69 on T cells stimulated through the TCR in the presence of RO4929097. In addition, we quantified CCR7 expression, which has been shown to be directly regulated by Notch signaling [44] . Following 24 h of stimulation, there were no significant differences in the percentage of TCR-activated T cells expressing CD25, CD69, or CCR7. However, there was a reproducible decrease in the percent of TCR-activated T cells that expressed CD25 and CD69 after treatment with either 1 lM or 10 lM RO4929097 suggesting that RO4929097 interferes with T-cell activation. Interestingly, the percentage of TCR-activated T cells expressing the chemokine receptor CCR7 was slightly increased following exposure to RO4929097 (Fig. 8) . These data suggest that RO4929097 inhibits T-cell activation, but paradoxically increases expression of CCR7 even though both T-cell activation and expression of CCR7 are under direct transcriptional control by Notch and normally up-regulated in activated T-cells.
Discussion
Numerous lines of evidence suggest targeting Notch signaling may specifically target breast cancer stem cells. RO4929097 is a potent and selective gamma secretase small-molecule inhibitor that targets cellular Notch processing and was reported to decrease NICD production and mRNA expression of Hes1 as well as to have anti-tumor activity in human lung cancer cells in a preclinical evaluation of the drug [37] . In the present study, we similarly found a reduction in the expression levels of Notch downstream target genes Hes1, Hey1, and HeyL in IBC cell lines. However, selective killing of putative cancer stem cell populations with drug alone or in combination with radiation was not observed. We demonstrate that this could be due to a redundancy and cross-talk in alternative pathways known to be involved in stem-cell self-renewal. We also demonstrated that IL-6 and IL-8 may further limit the efficacy of RO4929097 as a single agent in this IBC model system. Further, we demonstrated that RO4929097 inhibits production of the IL-8 mediator TNF-a from T cells, suggesting that testing with models that permit rigorous interrogation of microenvironmental influences on tumor efficacy may prove critical to fully evaluating this targeting strategy. We and others have previously reported the relative radioresistance of SUM149 cells [45, 46] . Under adherent culture conditions, these cells were radiosensitized by a combination treatment of radiation and ErbB inhibitor [45] . In this study, we explored the effect of RO4929097 on radiation sensitivity of SUM149 and SUM190 grown under culture conditions that promote 3D colony stem cell growth or standard 2D non-stem cell monolayer growth. We found that RO4929097 sensitized SUM190 cells to ionizing radiation in 2D culture, while it radioprotected both SUM149 and SUM190 cells in 3D culture. Moreover, while the inhibitor reduced 2D colony formation, it increased mammosphere formation in both cell lines. The increased stem cell activity observed in Notch inhibitor- treated cells may be due to redundant self-renewal pathways and we have shown that b-catenin and its downstream effector survivin are upregulated in Notch inhibitortreated stem cells after radiation (Fig. 4c, d ). In support of our data, Bouras et al. [47] have shown that inhibition of the Notch pathway in mammary stem cells enhances their stem cell potential. Two other studies have also demonstrated that Notch negatively regulates b-catenin protein levels in stem/progenitor cells [48, 49] . In these studies, an increase in TCF/b-catenin-dependent luciferase activity was observed in Notch siRNA-treated neural stem cells as well as in mouse cardiac progenitor cells lacking Notch1 in vivo and in vitro, indicating that Notch1 may function to negatively regulate b-catenin levels in stem-cell populations [48, 49] . Thus, combination strategies with additional targeting agents should be explored.
Another explanation for the increase in mammosphere formation and radioprotection effect seen with RO4929097 treatment in our study could be due to the high expression and/or induction of the IL-6 and IL-8 cytokines. In a previous study with RO4929097, the IL-6 receptor was upregulated in a microarray expression data in preclinical studies of human non-small cell lung carcinoma cells [37] , and recently the same group reported that high tumor levels of IL-6 and IL-8 abrogated the preclinical efficacy of RO4929097 [38] . Consistent with this observation, we found high levels of IL-6 and IL-8 produced in culture supernatants of both IBC cell lines used in this study compared to those of non-IBC cells (Fig. 6) . Sansone et al. [50] showed that treatment with IL-6 triggered Notch3-dependent upregulation of the Notch ligand JAG1 and promoted primary human mammospheres and MCF-7-derived mammosphere growth. Thus, IL-6 supports cancer stem cell renewal in breast cancer mammospheres via Notch3 [50] and the increase in the IL-6 receptor following RO4929097 treatment may represent a regulatory compensation for the loss of Notch signaling. Barsky's group has also recently reported the enrichment of Notch3 in the CSC-like subpopulation and its co-localization with ALDH1 within the lymphovascular emboli of Mary-X [15] . IL-6 also enhanced the proliferation of colon CSCs and lung CSCs [51, 52] . Moreover, there is evidence that increased IL-6/IL-8 signaling is associated with radioresistance in Stat1-overexpressing tumor cells and treatment with neutralizing antibodies to both cytokines is associated with activation of apoptotic cell death and sensitization to radiation [53] . Furthermore, another interesting recent finding demonstrated that IL-6 can reprogram differentiated cells to the cancer stem cell-like phenotype in breast and prostate cell lines and in cells derived from human breast tumors [54] . Thus, the failure of the Notch inhibitor RO4929097 to radiosensitize and inhibit mammosphere formation in IBC cell lines may be attributed to increased IL-6/IL-8 signaling in these cell lines which promoted CSC features. Future experiments should test the effect of tumor-derived IL-6/IL-8 on mammosphere formation. Charafe-Jauffret et al. showed that IL-8 could increase tumorsphere formation and Aldefluor positivity in the metaplastic SUM159 cell line [5, 16] . However, a concentration of 100 ng/ml was required for a significant increase in stem cell activity. In contrast, although IL-8 was detected in the supernatants of SUM159 cultures/3D mammospheres in the current study, the levels were about 20 times lower than the exogenous concentrations required for increased sphere formation. We also observed lower concentrations of both IL-6 and IL-8 in 3D cell culture, but these cultures contained fewer viable cells. However, the biologic activity of endogenous paracrines may be observed at lower concentrations than that of exogenous factors since it is released in close proximity to the receptor. Furthermore, the high level of cell aggregates in 3D culture might produce locally high concentrations of IL-6 and IL-8. Therefore, the lower levels of IL-6 and IL-8 observed in 3D culture supernatants may not reflect the optimal biologic activity of these factors.
Cytokine profiling from the serum of IBC patients has shown increased levels of IL-6 and IL-8 [55] . As signaling through IL-6 and IL-8 can be mediated in vivo by adaptive immune responses, we tested the effect of RO4929097 on cytokine production by TCR-activated T cells. This would suggest greater efficacy in vivo could be expected if the effect of RO4929097 on T cells might reduce the antagonistic effects of IL-6 and IL-8. We found that RO4929097 can reduce the production of inflammatory cytokines by activated T cells, particularly TNF-a. Although T cells contribute only a minor portion of the TNF-a within a tissue or in circulation, in an inflammatory environment, innate immune cells can potentially produce the majority of inflammatory cytokines. In IBC, Van Laere showed that overexpression of NF-kB is a hallmark of the disease [56, 57] . One of the most potent activators of NF-kB is TNF-a. In particular, TNF-a (and IL-1b) can elicit expression of IL-8 [58, 59] .
T cells are responsible for coordinating the antigenspecific inflammatory response by producing pro-inflammatory TH1 cytokines such as IFN-c, IL-2, and TNF-a, or ''anti-inflammatory'' TH2 cytokines such as IL-4, IL-5, IL-10, and IL-13. Both CD8 T-cytotoxic cells and CD4 T-helper cells can produce TNF-a following activation through the TCR [60] . Notch has been known for long as essential in T-cell development; however, more recent work has shown that Notch signaling may play a critical role in both T-cell activation and TH differentiation [36] . There are putative Notch/RBP-J binding sites in the promoter of the TH2 transcription factor Gata3 [61] and the TH1 transcription factor T-bet [62] . Therefore, we hypothesized that in vivo inhibition of Notch signaling with the gamma-secretase inhibitor RO4929097 could decrease the production of inflammatory cytokines by T cells that promote breast cancer stem cell maintenance. Indeed, our in vitro results confirm inhibition of T-cell activation by RO4929097, specifically of TNF-a which may increase the enthusiasm for further in vivo testing in immunocompetent animal models and further underscore the need for an immune competent animal model for IBC.
It has yet to be determined whether RO4929097 inhibits all four Notch family members or not. Differences in the expression levels of these Notch members in breast CSCs have been observed in different studies. For example, Harrison et al. [21] reported that sphere-derived stem cells and CD44
? CD24 -cells from breast cancer cell lines and patient samples possessed elevated expression of Notch4, but not Notch-1. They found Notch-4 inhibition was more effective in reducing tumor initiation than targeting Notch-1 suggesting breast CSCs rely preferentially on Notch4 signaling [21] . In another study, Xiao et al. [15] reported that ALDH1? subpopulation exhibited enriched Notch3 downstream signaling and co-localization of Notch3 and ALDH1 were demonstrated within the lymphovascular emboli of Mary-X. Detailed understanding of the role of Notch signaling in breast CSC survival and self-renewal depends on studying each receptor and ligand and their specific interactions and the relative roles of specific Notch members in individual cancers.
In summary, the Notch inhibitor RO4929097 did not inhibit putative cancer stem cells alone or with ionizing radiation in the IBC cell lines tested. This may be due to redundant self-renewal pathways or secretion of selfrenewal promoting cytokines either intrinsically or extrinsically. However, the in vivo effects may mediate be sensitive to microenvironment alternations such as the decrease in inflammatory factors by immune cells shown here. Careful assessment of multiple target strategies and rigorous modeling of the microenvironmental influences may shed further light on the potential of targeting Notch using RO4929097.
